AIM - NIID currently testing it and safe - COVID / CANCER / CFS
Updated
CHECK Ampligen has been used in humans for years for CFS - very similar to Long Haul Covid
CHECK - Industry renown thought leader who is Director of the WHO has been working on Ampligen through Japan NIID
CHECK - Roswell and other top cancer researchers have been ramping up testing of Ampligen
CHECK - company has about $1.40 in net cash and restructured in 2016
CHECK - Neal Burnette godfather of vaccines is on Ampligens board as of 2016
CHECK - Ampligen is a TLR3 agonist which decreased viral yields in Sars and now might work as a intranasal prophylaxis
UNCHECK - valuation of co. is less than 50mm does not compute give safety history and multiple at bats in cancer covid and CFS
CHECK - Industry renown thought leader who is Director of the WHO has been working on Ampligen through Japan NIID
CHECK - Roswell and other top cancer researchers have been ramping up testing of Ampligen
CHECK - company has about $1.40 in net cash and restructured in 2016
CHECK - Neal Burnette godfather of vaccines is on Ampligens board as of 2016
CHECK - Ampligen is a TLR3 agonist which decreased viral yields in Sars and now might work as a intranasal prophylaxis
UNCHECK - valuation of co. is less than 50mm does not compute give safety history and multiple at bats in cancer covid and CFS
Trade active
this is just the beginning folks, co. should be valued around 500mm = $13.00 and even then I would hold for everything they have going on... the person on their Special Advisory Board is a rockstar - bascially founded Amgen and their also working with Asagawa head of NIID WHO who loves Ampligen and is working with it right now... safe profile, let along all the work going on with CFS - watch the movie Forgotten Plague on Amazon - their stuff works with CFS if only Trump woke up to this.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.